DCM
ADAP

DAFNA Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

DAFNA Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-341,064
Closed -$324K – 83
2024
Q3 		$324K Hold
341,064
– – 0.08% 78
2024
Q2 		$333K Hold
341,064
– – 0.08% 76
2024
Q1 		$539K Sell
341,064
-10,000
-3% -$12.1K 0.12% 65
2023
Q4 		$278K Hold
351,064
– – 0.07% 67
2023
Q3 		$274K Hold
351,064
– – 0.09% 66
2023
Q2 		$325K Hold
351,064
– – 0.09% 66
2023
Q1 		$383K Hold
351,064
– – 0.11% 65
2022
Q4 		$513K Hold
351,064
– – 0.14% 62
2022
Q3 		$377K Hold
351,064
– – 0.1% 79
2022
Q2 		$597K Hold
351,064
– – 0.16% 71
2022
Q1 		$723K Buy
351,064
+214,798
+158% +$580K 0.19% 76
2021
Q4 		$511K Buy
+136,266
New +$620K 0.13% 80
2016
Q3 		– Sell
-24,955
Closed -$203K – 78
2016
Q2 		$203K Sell
24,955
-63,145
-72% -$595K 0.16% 79
2016
Q1 		$716K Buy
88,100
+40,000
+83% +$327K 0.62% 46
2015
Q4 		$580K Buy
+48,100
New +$471K 0.52% 49

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DAFNA Capital Management's ADAP Position: Q4 2024 in Review

DAFNA Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2024, closing a stake of 341,064 shares — an estimated $324K sold.

DAFNA Capital Management first reported a position in ADAP in Q4 2015 and held it in 15 quarters. The position peaked at $723K in Q1 2022. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

  • DAFNA Capital Management reported no remaining Adaptimmune Therapeutics position as of Q4 2024 after selling out during the quarter.
  • DAFNA Capital Management sold 341,064 Adaptimmune Therapeutics shares in Q4 2024, an estimated $324K.
  • DAFNA Capital Management first reported a position in Adaptimmune Therapeutics in Q4 2015 and held it in 15 quarters.
  • DAFNA Capital Management's Adaptimmune Therapeutics position peaked at $723K in Q1 2022.
  • 80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on DAFNA Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.